We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?

作者：Fragoso Yara D^*; Arruda Niedja M; Arruda Walter O; Brooks Joseph B B; Correa Eber C; Damasceno Alfredo; Damasceno Carlos A; Ferreira Maria L B; Giacomo Maria C B; Gomes Sidney; Goncalves Marcus V M; Grzesiuk Anderson K; Kaimen Maciel Damacio R; Lopes Josiane; Machado Suzana C N; Oliveira Celso L S; Stella Carla R A V

来源：Expert Review of Neurotherapeutics, 2014, 14(2): 127-130.

DOI：10.1586/14737175.2014.874947

• fingolimod
• JC virus
• multiple sclerosis
• natalizumab
• relapses

Natalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendations.

• 出版日期2014-2